Evidence map›Paper›PMID 31431711›Full record

ArticleBone marrow transplantation2019

Ex vivo expansion of autologous, donor-derived NK-, γδT-, and cytokine induced killer (CIK) cells post haploidentical hematopoietic stem cell transplantation results in increased antitumor activity.

Patrick Schlegel, Anne-Marie Lang, Marie Matela, Annika Horrer, Anne Schilling, Alexander Jöchner, Max Wiedenmann, Christian Seitz, Michaela Döring, Tobias Feuchtinger and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Patrick SchlegelUniversity Children's Hospital, Department of Pediatric Hematology and Oncology, University of Tuebingen, Tuebingen, Germany. patrick.schlegel@med.uni-tuebingen.de.
Anne-Marie LangUniversity Children's Hospital, Department of Pediatric Hematology and Oncology, University of Tuebingen, Tuebingen, Germany.
Marie MatelaUniversity Children's Hospital, Department of Pediatric Hematology and Oncology, University of Tuebingen, Tuebingen, Germany.
Annika HorrerUniversity Children's Hospital, Department of Pediatric Hematology and Oncology, University of Tuebingen, Tuebingen, Germany.
Anne SchillingUniversity Children's Hospital, Department of Pediatric Hematology and Oncology, University of Tuebingen, Tuebingen, Germany.
Alexander JöchnerUniversity Children's Hospital, Department of Pediatric Hematology and Oncology, University of Tuebingen, Tuebingen, Germany.
Max WiedenmannUniversity Children's Hospital, Department of Pediatric Hematology and Oncology, University of Tuebingen, Tuebingen, Germany.
Christian SeitzUniversity Children's Hospital, Department of Pediatric Hematology and Oncology, University of Tuebingen, Tuebingen, Germany.
Michaela DöringUniversity Children's Hospital, Department of Pediatric Hematology and Oncology, University of Tuebingen, Tuebingen, Germany.
Tobias FeuchtingerDr. von Hauner University Children's Hospital, Department of Pediatric Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Munich, Germany.
Florian HeubachUniversity Children's Hospital, Department of Pediatric Hematology and Oncology, University of Tuebingen, Tuebingen, Germany.
Armin RabsteynUniversity Children's Hospital, Department of Pediatric Hematology and Oncology, University of Tuebingen, Tuebingen, Germany.
Rupert HandgretingerUniversity Children's Hospital, Department of Pediatric Hematology and Oncology, University of Tuebingen, Tuebingen, Germany.
Peter LangUniversity Children's Hospital, Department of Pediatric Hematology and Oncology, University of Tuebingen, Tuebingen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Posttransplant treatment strategies are narrowed by the vulnerability of bone marrow. Building on immune cells with antitumor activity is a growing field in cancer therapy. Thus, transfer of expanded and preactivated immune cells is a promising intensification of treatment in high-risk tumor patients. We tested ex vivo expanded NK-, γδT-, and CIK cells that were generated by coincubation with irradiated K562-mb15-41BBL and Il2 and compared the expansion conditions of PBMCs versus CD3-depleted PBMCs as well as static versus semi-automated expansion. The median fold expansion was significantly higher using PBMCs and static expansion conditions. Expanded cells were preactivated with a CD56

Indexed as

Cytokine-Induced Killer CellsHematopoietic Stem Cell TransplantationHumansImmunophenotypingKiller Cells, NaturalTransplantation ConditioningTransplantation, Haploidentical

Identifiers

PMID31431711

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.